Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;17(11):2179-2181.
doi: 10.1016/j.cgh.2019.04.026. Epub 2019 Apr 17.

Simple Clinical Tools to Predict Decompensation in Patients With Compensated Cirrhosis: An Unmet Need

Juan G Abraldes  1 , Guadalupe Garcia-Tsao  2
Affiliations
Editorial

Simple Clinical Tools to Predict Decompensation in Patients With Compensated Cirrhosis: An Unmet Need

Juan G Abraldes et al. Clin Gastroenterol Hepatol. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors disclose no conflicts.

Figures

Figure 1.
Figure 1.
Graphical representation in the form of a nomogram of the model described by Ripoll et al. This model was derived by Cox regression in 213 patients with compensated cirrhosis without varices. The upper panel is used to derive the points contributed for each variable. The total number of points is then used in the lower panel to derive the probability of remaining decompensation-free at 1, 2, and 3 years. ALB, albumin; AST, aspartate aminotransferase; MELD, Model for End-Stage Liver Disease; PLT, platelet count
See this image and copyright information in PMC

Comment on

References

    1. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65:310–335. - PubMed
    1. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133:481–488. - PubMed
    1. Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 2018;155:1140–1153. - PubMed
    1. Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439–1447. - PubMed
    1. Robic MA, Procopet B, Metivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011;55:1017–1024. - PubMed